

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Heike PRINZ	09/26/2012
Bjorn SCHURAD	07/25/2012
RECEIVING PARTY DATA	
Name:	Acino AG
Street Address:	Am Windfeld 35
City:	Miesbach
State/Country:	GERMANY
Postal Code:	83714
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13518006
CORRESPONDENCE DATA	
Fax Number:	4408080657
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	440-808-0011
Email:	docket@patentandtm.com
Correspondent Name:	Curatolo Sidoti Co., LPA
Address Line 1:	24500 Center Ridge Rd.
Address Line 2:	Suite 280
Address Line 4:	Cleveland, OHIO 44145
ATTORNEY DOCKET NUMBER:	LAK.P10-069654
NAME OF SUBMITTER:	Joseph G Curatolo
Total Attachments: 4 source=LAK.P10-069654 Executed Assignment-Prinz#page1.tif source=LAK.P10-069654 Executed Assignment-Prinz#page2.tif source=LAK.P10-069654 Executed Assignment-Schurad#page1.tif source=LAK.P10-069654 Executed Assignment-Schurad#page2.tif	

OP \$40.00 13518006



ASSIGNMENT

IN CONSIDERATION of the sum of One Dollar (\$1.00), or the equivalent thereof, and other good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, we, Heiko ~~HAUSNER~~ PRINZ and Björn SCHURAD, do hereby sell, assign and transfer to ^{HP 26. Sept 2012} Acino AG, a corporation organized and doing business under the laws of Germany, having a place of business at Am Windfeld 35, Miesbach, 83714, Germany, and its successors and assigns the entire right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the invention

Transdermal Therapeutic System For Administering Rivastigmine Or Derivatives Thereof
invented by us and described in application for United States Letters Patent submitted on 21 June 2012, as the U.S. national stage of PCT/EP2010/069654, bearing U.S. Serial Number 13/518,006 and claiming priority from European Patent Application No. 09180413.8, filed 22 December 2009; and from European Patent Application No. 10154648.9, filed 25 February 2010, and (1) said application for United States Letters Patent and all continuations, continuations-in-part and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations of continuations), (2) all United States Letters Patent which may be issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions of and reexamination certificates issued for all such United States Letters Patent, (5) all applications for Letters Patent therefor in all countries and territories of the world (including all applications for divisions of such applications), and (6) all Letters Patent which may be granted and/or issued therefor in all of said countries and territories (including all modifications and extensions thereof and supplemental protection certificates relating thereto), the said interest being the entire ownership of said invention and all of said applications, Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by Acino AG and its successors and



assigns to the full end of the terms to which said Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

And we hereby agree that during and/or subsequent to our employment or contract we will sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution in the United States and all countries foreign thereto of all of said applications for said Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.


 Helke HAUSNER-PRINZ Date 26. Sept 2012

 Witness Prinz Oliver

Björn SCHURAD Date _____

Witness _____

Accepted:  
 For: _____ Date 15. October 2012
 Jörg SCHEIDLE Robert SCHMID Acino AG Date _____

ASSIGNMENT

IN CONSIDERATION of the sum of One Dollar (\$1.00), or the equivalent thereof, and other good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, we, Heike HAUSNER and Björn SCHURAD, do hereby sell, assign and transfer to Acino AG, a corporation organized and doing business under the laws of Germany, having a place of business at Am Windfeld 35, Miesbach, 83714, Germany, and its successors and assigns the entire right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the invention

Transdermal Therapeutic System For Administering Rivastigmine Or Derivatives Thereof

invented by us and described in application for United States Letters Patent submitted on 21 June 2012, as the U.S. national stage of PCT/EP2010/069654, bearing U.S. Serial Number 13/518,006 and claiming priority from European Patent Application No. 09180413.8, filed 22 December 2009; and from European Patent Application No. 10154648.9, filed 25 February 2010, and (1) said application for United States Letters Patent and all continuations, continuations-in-part and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations of continuations), (2) all United States Letters Patent which may be issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions of and reexamination certificates issued for all such United States Letters Patent, (5) all applications for Letters Patent therefor in all countries and territories of the world (including all applications for divisions of such applications), and (6) all Letters Patent which may be granted and/or issued therefor in all of said countries and territories (including all modifications and extensions thereof and supplemental protection certificates relating thereto), the said interest being the entire ownership of said invention and all of said applications, Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by Acino AG and its successors and

LAK.P10-069654

assigns to the full end of the terms to which said Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

And we hereby agree that during and/or subsequent to our employment or contract we will sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution in the United States and all countries foreign thereto of all of said applications for said Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.

Heike HAUSNER

Date

Witness


Björn SCHURAD



25 July 2012

Date

Witness

Accepted:

Name

 
Jörg Schendle Robert Schmid
Vorstand

For:

Acino AG

08/08/2012

Date

